Article and Video CATEGORIES
Estelamari Rodriguez, MD, MPH
Associate Director for Community Outreach
Thoracic Oncology Division
Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
We are pleased to offer more additions to our Lung Cancer Video Library for our Spanish speaking community.
Para las nuevas incorporaciones a nuestra videoteca de cáncer de pulmón, producida en español para nuestra comunidad latina, la Dra. Estelamari Rodríguez nos brinda la información más reciente sobre la atención del cáncer de pulmón. En este video, el Dr. Rodríguez analiza el estado actual de la carga mutacional tumoral en 2020 como un factor de respuesta predictivo.
*****
For the newest additions to our Lung Cancer Video Library, produced in Spanish for our Latino Community, Dr. Estelamari Rodriguez provides us with the latest information in lung cancer care. In this video, Dr. Rodriguez discusses the current status of tumor mutational burden in 2020 as a predictive response factor.
Para unirse a la conversación, visite https://cancergrace.org/forum.
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…